Kymera Therapeutics has delivered very strong share-price gains in recent years, and that kind of move naturally raises the question of whether the current valuation is still grounded in its underlying book value. With the stock now in a very different place than it was a few years ago, investors are asking how much of the story is already reflected on the balance sheet. Over the past 3 years the share price has climbed by more than 7x. That puts real weight on the question of how its...
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-579 in healthy volunteers on Thursday, October 29, 2026, as part of its previously scheduled third quarter 2026 financial results. The Company will host a video confe
Kymera Therapeutics (KYMR) eyes pivotal BROADEN2 Phase 2b data for KT-621, a STAT6 degrader in atopic dermatitis—upside vs. Dupixent. See more here.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $137.73, according
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.
Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET;Citi 2026 Biopharma Back to School Summit in New Yor
Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.